Yayın:
Design and synthesis of novel cylopentapyrazoles bearing 1,2,3-thiadiazole moiety as potent antifungal agents

dc.contributor.authorGiray, Betul
dc.contributor.authorKaradag, Ayse Esra
dc.contributor.authorIpek, Ozgecan Savlug
dc.contributor.authorPekel, Hanife
dc.contributor.authorGuzel, Mustafa
dc.contributor.authorKucuk, Hatice Baspinar
dc.date.accessioned2026-06-27T14:30:13Z
dc.date.issued2020
dc.description.abstractIn drug-resistant phytopathogenic fungi, there has been extensive research on microbiological and antifungal drug development. In this study, a novel series of cylopentapyrazole bearing a 1,2,3-thiadiazole ring 2a-e were designed and synthesized according to the principle of combination of bioactive structures. Thus, we have employed a [3 + 2] cycloaddition with 4-methyl-[1,2,3] thiadiazole-5-carboxylic acid hydrazones 1a-e and cyclopentadiene ring. Novel synthesized compounds were identified with IR, H-1 and C-13 NMR, mass spectrometry and elemental analysis then, antifungal activities were assayed. Based on our study, a combination of the compounds 1a and 2b possess remarkable antifungal activity against Botrytis cinerea AHU 9424 with 100% inhibition. EC50 values were calculated by studying different doses in combinations with high inhibition rates. The combination of 1a + 2b has an EC50 value at 6.37 and 13.85 mu g/ml concentrations against B. cinerea and F. culmorum, respectively. The combination of compound 1a + 2b, having a cylopentapyrazole ring on the 1,2,3-thiadiazole backbone, shows promising fungicidal activity and deserves further development. Additionally, the homology model of the CYP51 enzyme that belongs to Fusarium moniliforme was generated using CYP51B (PDB ID: 6CR2), and molecular docking was performed using this homology model for each compound. The results of this study clearly indicate that these novel compounds can be identified as promising lead compounds and potential fungicidal agents in future.en
dc.description.urihttps://doi.org/10.1016/j.bioorg.2019.103509
dc.identifier.doi10.1016/j.bioorg.2019.103509
dc.identifier.eissn1090-2120
dc.identifier.issn0045-2068
dc.identifier.pubmed31884141
dc.identifier.urihttps://hdl.handle.net/20.500.14981/61377
dc.identifier.volume95
dc.identifier.wos000512762900030
dc.language.isoeng
dc.publisherACADEMIC PRESS INC ELSEVIER SCIENCE
dc.relation.ispartofBIOORGANIC CHEMISTRY
dc.subjectCylopentapyrazole
dc.subject1,2,3-thiadiazole
dc.subjectAntifungal activity
dc.subjectFungicide
dc.subjectPlant pathogen
dc.subjectNovel antifungal drug development
dc.subjectDocking
dc.subjectMolecular modelling studies
dc.subjectPYRAZOLE DERIVATIVES
dc.subjectINSECTICIDAL ACTIVITIES
dc.subjectBIOLOGICAL EVALUATION
dc.subjectACID-DERIVATIVES
dc.subjectINHIBITORS
dc.subjectHYDRAZONE
dc.subjectSEARCH
dc.subjectETHER
dc.subjectBiochemistry & Molecular Biology
dc.subjectChemistry
dc.titleDesign and synthesis of novel cylopentapyrazoles bearing 1,2,3-thiadiazole moiety as potent antifungal agents
dc.typeArticle
dspace.entity.typePublication
local.import.sourceWOS

Dosyalar

Koleksiyonlar